COVID-19: the tipping point for digital transformation in biopharma
Digital transformation in sales, marketing and medical has generally been slow in life sciences companies. Digital budgets have nudged up only slowly (and were mostly spent on technology), while capability levels have remained subpar. Indeed, well below 10% fully believe their staff are well trained in digital (2018-2020 Across Health Maturometer™).
With the arrival of COVID-19, the offline customer engagement model (which represented 95% of commercial budgets vs 5% for digital) came to a grinding halt. At the same time, customer expectations increased, with close to 60% of HCPs finding digital services by pharma important – but only 36% are satisfied.
Capability-building at scale in the next normal
Similar to other industries, life science companies need to boost their customer engagement teams’ capabilities quickly (skills and knowledge, powered by a positive mindset) – across all customer-facing teams (sales, marketing, medical, access, patient affairs, etc.), all over the world. Meet Scala365™ by Across Health, an evidence-based, hypertargeted capability-boosting product suite for life sciences:
Our track record
Across Health has a deep expertise in both traditional/F2F capability-building as well as online and blended learning. For instance, during the COVID-19 crisis, it opened up its 15 eLearning modules for free to the industry, with over 3,500 participants and over 20,000 courses taken. And what makes Scala365 truly unique, is that it is evidence-based: key Navigator365™ findings, Maturometer™ data and well-metricized case studies constitute the core of the Scala365 assets.
Interested? Reach out to us here